



Bringing Pharmaceutical Innovation to the World

CONTENTS

1	Mission Statement	16	Ophthalmic Pharmaceuticals	42	Executive Committee
4	Financial Overview	22	BOTOX/Neurotoxin	44	Board of Directors
6	Letter to Investors	28	Skin Care	46	Financials
10	Research and Development	32	Ophthalmic Surgical	51	Corporate Overview and Stockholders' Information
12	Technology Pipeline	38	Contact Lens Care Products		

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Any statements in this report that refer to Allergan's estimated or anticipated future results, including, by way of example only, statements in the "Spin off of the Optical Medical Devices Businesses", "Outlook" and "Technology Pipeline" segments; aspirations for sales, market share and EPS growth; top quartile value creation; intentions to drive efficiencies; discussions of the R&D pipeline, its funding, and its potential as a source of long-term financial growth; discussions of potential uses for the Company's technology and products, future products, future product approvals, product launches or future approvals for indications regarding previously approved products; plans for clinical trials, market-share objectives and regulatory filings; and statements regarding the proposed spin off transaction described in this report are forward-looking statements.

All forward-looking statements in this report reflect the Company's current analysis of existing trends and information and represent the Company's judgment only as of the date of this report. Actual results may differ from current

cost containment reforms; technological advances and patents obtained by competitors; the performance, including the approval, introduction and consumer acceptance of new products and continuing acceptance of currently marketed products; the effectiveness of consumer advertising and promotional campaigns; the timely and successful implementation of strategic initiatives including, by way of example only, the consummation of the spin off transaction described in this report; the uncertainty associated with the identification of and successful consummation and execution of external corporate development transactions; and Allergan's ability to obtain and maintain a sufficient supply of its products to meet market demand in a timely manner. In addition, matters generally affecting the economy, such as changes in interest and currency exchange rates and the state of the economy worldwide, can affect the Company's results. Therefore, the reader is cautioned not to rely on these forward-looking statements. The Company disclaims any intent or obligation to update these forward-looking statements. Additional information concerning the factors that affect Allergan's businesses can be found in Allergan press releases as well as Allergan's periodic

OUR MISSION

TO BECOME THE PARTNER OF CHOICE FOR EVER BETTER HEALTH CARE THROUGH THE VALUE OF OUR TECHNOLOGICAL INNOVATION, INDUSTRY LEADERSHIP, PARTNERING SKILLS AND RELATIONSHIPS, WORLDWIDE INFRASTRUCTURE, RESEARCH AND MANUFACTURING CAPABILITIES.

TO DEVELOP A UNIQUE LEVEL OF UNDERSTANDING OF OUR CUSTOMERS IN ORDER TO IMPLEMENT OPERATIONAL STRATEGIES THAT PROVIDE THE GREATEST VALUE FOR OUR CUSTOMERS AND STAKEHOLDERS.

OUR VISION

TO CONTINUE AS AN INNOVATIVE, TECHNOLOGY DRIVEN, GLOBAL HEALTH CARE COMPANY FOCUSED ON PHARMACEUTICALS IN SPECIALTY MARKETS THAT DELIVER VALUE TO CUSTOMERS, SATISFY UNMET MEDICAL NEEDS AND IMPROVE PATIENTS' LIVES.

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company that develops and commercializes specialty pharmaceutical products for the ophthalmic, neurological, dermatological and other specialty markets as well as ophthalmic surgical devices and contact lens care solutions.* Allergan markets products in over 100 countries worldwide that deliver value to our customers, satisfy unmet medical needs and improve people's lives.

Allergan has approximately 6,400 employees worldwide with 2001 sales of nearly \$1.7 billion. Allergan is differentiated from other specialty pharmaceutical companies through its discovery-to-development research programs and its global marketing and sales capabilities.

**In January 2002, Allergan announced plans to spin off its ophthalmic surgical device and contact lens care businesses. This transaction is expected to be completed in mid-2002 through a tax-free dividend to Allergan stockholders.*

OPHTHALMIC PHARMACEUTICALS



ACULAR
(ketorolac tromethamine ophthalmic solution 0.5%)
The No. 1 non-steroidal anti-inflammatory (NSAID) in the U.S. and used for a range of conditions including allergy, photophobia, post-surgical pain, and post-surgical inflammation.



ALOCRIL
(nedocromil sodium 2%)
A fast acting non-steroidal anti-inflammatory drug approved to treat the itch associated with ocular allergy.



ALPHAGAN
(brimonidine tartrate ophthalmic solution 0.2%)
The first alpha2-agonist approved for the long-term treatment of elevated intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. ALPHAGAN is the second largest product in glaucoma and in eye care pharmaceuticals worldwide.



ALPHAGAN P
(brimonidine tartrate ophthalmic solution 0.15%)
Preserved with PURITE: A new formulation containing brimonidine tartrate, a relatively selective alpha-2 agonist, which is the same active ingredient in ALPHAGAN. ALPHAGAN P is indicated for the lowering of IOP and is comparable in efficacy to ALPHAGAN with lower rates of ocular allergy.



LUMIGAN
(bimatoprost ophthalmic solution 0.03%)
The first synthetic prostamide analog and an important component in the Company's growing position as a leader in glaucoma management. It is indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measures over time) to another IOP-lowering medication.



OCUFLOX
(ofloxacin ophthalmic solution 0.3%)
Indicated for use in bacterial conjunctivitis and corneal ulcers and the No. 1 anti-infective prescribed by ophthalmologists in the U.S.



REFRESH TEARS
Artificial tear products for various needs led by the REFRESH brand which includes: REFRESH PLUS, the No. 1 unit dose product worldwide; REFRESH TEARS, the No. 1 multi-dose product in the U.S.; REFRESH P.M., for overnight relief of dry eye; REFRESH CONTACTS, relief from dryness and irritation for contact lens wearers; and REFRESH LIQUIGEL, a unique extra-strength formula containing one of the most effective lubricant and preservative systems,

BOTOX/NEUROTOXIN



BOTOX and BOTOX COSMETIC
(botulinum toxin type A)

The most widely used botulinum toxin product in the world and the foundation for Allergan's global leadership in neurotoxin therapy. As the primary treatment for many focal movement disorders since the mid-1980's, indications for BOTOX have expanded as scientists and physicians recognize its broad applicability.

- Facial Aesthetics (glabellar lines/brow furrow)
[Approved in 10 countries.](#)
- Cervical Dystonia (painful neck spasm)
[Approved in 49 countries.](#)
- Juvenile Cerebral Palsy (muscles of one or more limbs are permanently contracted and stiff making normal movement difficult in children)
[Approved in 43 countries.](#)
- Adult Spasticity (increased rigidity in a group of muscles, causing stiffness and restriction of movement)
[Approved in 18 countries.](#)
- Hyperhidrosis (excessive sweating)
[Approved in 10 countries.](#)

SKIN CARE

AZELEX

(azelaic acid cream 20%)

A mild emollient and moisturizing treatment indicated for mild-to-moderate acne that allows for use under makeup, moisturizers, sunscreens and other topical medications.

FLUOROPLEX

(fluorouracil 1%)

Indicated for the treatment of certain skin problems such as actinic (solar) keratoses (small red or skin color growths that appear as a result of over exposure to the sun).

MD FORTE

MD FORTE is a physician-recommended line of aesthetic skin care products containing alpha hydroxy acids for reducing the appearance of fine facial lines and wrinkles.

TAZORAC Gel

(tazarotene gel 0.05% and 0.1%)

A topical receptor-selective retinoid approved for the treatment of acne and psoriasis.

TAZORAC Cream

(tazarotene cream 0.05% and 0.1%)

A new formulation of the topical, receptor-selective retinoid delivers the same efficacy of the Gel while providing a new alternative for treating a broader range of patients with varied skin types and conditions.

OPHTHALMIC SURGICAL

AMADEUS

Allergan entered the refractive surgery market in September 2000 with the AMADEUS microkeratome. The AMADEUS is viewed by leading refractive surgeons as one of the finest, most reliable and most precise microkeratomomes on the market today.

ARRAY

The ARRAY silicone multifocal intraocular lens (IOL) provides a range of vision from near to far and significantly reduces the patient's dependence on eyeglasses. The ARRAY provides distance vision comparable, and near vision superior, to monofocal IOLs and is the only multifocal IOL marketed in the U.S.

CLARIFLEX

The CLARIFLEX with its unique OptiEdge design is a third-generation silicone monofocal IOL that has been shown to reduce internal reflections and glare.

SENSAR with OptiEdge

A new acrylic monofocal IOL with the patented OptiEdge design was developed to have a sharp, vertical edge on the posterior side where it comes in contact with the lens capsule and a round anterior surface to reduce unwanted reflections.

SOVEREIGN with WHITESTAR

The new WHITESTAR technology allows for a dramatic decrease in the amount of energy delivered to the eye. It is the most sophisticated phacoemulsification system in the global market with advanced sensors to control fluidics during irrigation and aspiration in small-incision cataract surgery.

The UNFOLDER

The UNFOLDER Gold, Silver and Sapphire IOL implementation systems ensure controlled and predictable release of the IOL into the eye, delivering the lens when and where the surgeon wants it – inside the eye's capsular bag.

CONTACT LENS CARE

COMPLETE

A proprietary multi-purpose solution for all soft contact lenses which has a built-in lubricant to help provide more comfortable lens wear. COMPLETE is also the fastest growing multi-purpose solution in the world, growing at a rate of nearly 3:1 over the competition.

COMPLETE BLINK-N-CLEAN

These contact lens drops offer a unique blend of gentle-to-the-eye cleaning agents in a tear-like formula that conveniently dissolves away material that causes irritation and discomfort.

CONTACT LENS CARE

As the No. 2 contact lens care company in the world and the No. 1 company in Europe and Japan (excluding heat-based system products), other leading worldwide product offerings include: CONCEPT F, OXYSEPT 1-STEP, ULTRACARE, ULTRAZYME and TOTAL CARE.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.